Cleveland Clinic cancer researchers are involved with more than 50 studies that’ll be presented at the virtual American Society of Clinical Oncology (ASCO) Annual Meeting, June 4—8, 2021.
Key research from Cleveland Clinic focuses on advancements in the prevention and risk reduction in hereditary breast cancer; care delivery, including value of care and disparities in research funding; and care quality improvement related to COVID-19. Some research highlights our experts can discuss are listed below. They can also provide outside perspective on other ASCO presentations.
- Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in neuroendocrine tumors
- Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer
- Ancestrally unbiased polygenic breast cancer (BC) risk assessment
- Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma
- SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691)
- Choosing unwisely: Low-value care in older adults with a diagnosis of myelodysplastic syndrome
- Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients
- Initial report on hospitalized cancer patients with COVID-19 from the National Cancer Institute (NCI) COVID-19 in Cancer Patients Study (NCCAPS)
RSS